

Physician Signature: \_

FAX: 626-798-8376

\_ Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

1719 E. Walnut St. Pasadena, CA 91106 Tel: 626-798-6789

## HEPATOLOGY ENROLLMENT FORM

		PATIENT INFORMATION			
Name (First, Last):			<b>_</b> _ Male _	Female	
Address:		City:	State: Zip Code:		
Phone: ( )	Date of Birth (	mm/dd/yyyy):/ S	ocial Security #		
	PLEASE FA	X COPY OF INSURANCE CARD (Front & Back)			
Medication	Dose/Strength	Directions	Quantity	Refills	
□ DAKLINZA	□ 30mg	T.1. 1.11. PO OD C. 20.1	20		
	□ 60mg □ 90mg	Take 1 tablet PO QD for 28 days	28		
□ EPCLUSA	□ 400mg/100MG	Take 1 tablet PO QD for 28 days	28		
□ HARVONI	□ 90mg/400mg	Take 1 tablet PO QD for 28 days	28		
□ MAVYRET	□ 100mg/40mg	Take 3 tablets PO With Food QD for	28 days 84		
□ RIBAPAK	□ 400mg/400mg	□ 400mg A.M & 400mg P.M			
	□ 600mg/400mg	□ 600mg A.M & 400mg P.M	28		
- VIEWDA BAW	□ 600mg/600mg	☐ 600mg A.M & 400mg P.M  Take 3 tablets by mouth in the morning	ng and 1 tablet by		
□ VIEKIRA PAK	□ 250mg/12.mg/75mg/50mg	mouth in the evening with food	112		
<ul><li>□ ZEPATIER</li><li>□ VIREAD</li></ul>	□ 50mg/100mg □ 300mg	Take 50 mg/100 mg by mouth once of Take 1 tablet PO QD	daily 28	_	
□ VEMLIDY	□ 25mg	Take 1 tablet PO QD	30	+	
□ OTHER					
DIAGNOSIS AND CLI	NICAL INFORMATION				
Diagnosis: □ B18.2 (Chi	ronic Hepatitis C Virus)   Other	Prior Regimen	Prior Regimen □ Naïve□Experienced (List below)		
Diagnosis date:		Previous Treatme	Previous Treatment		
Genotype: □ 1 □ 2 □ 3	$\square$ 4 $\square$ 5 $\square$ 6		If Yes, was patient a □ Non-Responder□Responder□Relapsed		
Baseline viral load:			IL28B polymorphism:□ CC □CT □TT		
	□ F1□ F2 □ F3 □ F4 □	, ,	Other Comorbidities		
	ompensated   Decompensated	Allergies		_	
Co-infection(s): ☐ None	•				
	☐ Pre-transplant ☐ Post-transplant	Date:			
Tansplant status. 🗀 14/7	L I Te-transpiant L Tost-transpiant	Butc			
Total # of Dangero	us Drugs Prescribed				
		PRESCRIBER'S INFORMATION			
Prescriber Name (First			NPI#:		
		State: Zip Code:			
		Contact Name:			

I authorize 986 Specialty Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process

IMPORTANT NOTICE: This facsimile is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.

be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.